Ernexa Therapeutics Inc. Business Acquisition, Pro Forma Revenue
Ernexa Therapeutics Inc. (ERNA) reported Business Acquisition, Pro Forma Revenue of $24.06 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-29.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2013-03-29
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for the quarter ending 2012-12-31 was $24.05M, a 1.76% decline year-over-year.
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for the quarter ending 2012-09-30 was $6.05K, a 0.88% decline year-over-year.
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for the quarter ending 2011-12-31 was $24.48M.
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for the quarter ending 2011-09-30 was $6.10K.
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for fiscal 2012 was $24.06M, a 1.76% decline from fiscal 2011.
- Ernexa Therapeutics Inc. business acquisition, pro forma revenue for fiscal 2011 was $24.50M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2012-12-31 | $24.05M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $24.05M derived: sum of 2 quarters · filed 2013-03-29 | $24.06M 10-K · filed 2013-03-29 | |
| 2012-09-30 | $6.05K 10-Q · filed 2012-11-09 | $18.13K 10-Q · filed 2012-11-09 | ||
| 2011-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $24.48M derived: sum of 2 quarters · filed 2013-03-29 | $24.50M 10-K · filed 2013-03-29 | |
| 2011-09-30 | $6.10K 10-Q · filed 2012-11-09 | $18.39K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |